Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Total Liabilities
Everything the company owes to creditors and other parties.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 83.1% from a year ago
Total liabilities stood at $11.6M at the end of Q1 FY2026, up 83.1% from a year earlier and up 10.0% from the prior quarter. Over 3 fiscal years it compounded at -38.2% a year.
Context
- Total liabilities amounted to 11.8% of total assets at the end of Q1 FY2026, up 7.7 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +83.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.55M USD
- Year-over-year change
- -92.0%
- 3-year CAGR
- -38.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.55M | -92.0% |
| FY2024 | 2024-12-31 | 132.15M | +191.5% |
| FY2023 | 2023-12-31 | 45.34M | +1.5% |
| FY2022 | 2022-12-31 | 44.68M | — |
Total Liabilities vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 total liabilities of $11.6M is the 10th highest of the 11 companies compared; the peer median is $33.2M.
- Its year-over-year change of +83.1% is the 3rd highest of 11, against a peer median of -3.2%.
- Total liabilities amounts to 11.8% of total assets for AARD, versus a peer median of 26.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $298.58M | -6.8% | -8.8% | 134.4% | |
| Mar 2026 | $198.12M | -13.7% | +53.9% | 63.0% | |
| Mar 2026 | $46.98M | -16.8% | -10.0% | 31.5% | |
| Mar 2026 | $36.9M | -48.7% | +38.5% | 15.7% | |
| Mar 2026 | $33.36M | +0.3% | -0.9% | 18.8% | |
| Mar 2026 | $33.03M | +0.8% | -9.0% | 51.4% | |
| Mar 2026 | $31.57M | +98.4% | -9.0% | 31.6% | |
| Mar 2026 | $28.88M | +17.6% | -12.7% | 21.4% | |
ZURAZura Bio Limited | Mar 2026 | $11.75M | -44.3% | -23.1% | 5.1% |
| Mar 2026 | $11.6M | +83.1% | -38.2% | 11.8% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $9.2M | +318.0% | -29.3% | 6.3% |
| Peer median (excluding AARD) | $33.2M | -3.2% | -9.0% | 26.5% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.